Senescent Cells — "Zombie Cells" That Refuse to Die and Actively Poison Surrounding Tissue — Accumulate With Age and Drive Multiple Hallmarks of Aging: Baker 2011 in Nature Proved That Clearing Them Extended Lifespan, and a New Class of Drugs Called Senolytics Is Now in Human Trials

causal proof — Baker et al. 2011 (Nature): the experiment that established cellular senescence as a causal driver of age-related tissue dysfunction, not merely a correlate; the model: BubR1H/H progeroid mice — mice with accelerated aging due to a spindle assembly checkpoint mutation; by 5 months, these mice have muscle wasting, cataracts, fat loss, and dramatically reduced lifespan; the genetic tool: INK-ATTAC transgene, a construct that expresses an inducible suicide gene (FK506-binding-protein-Caspase 8 fusion) specifically under the p16Ink4a promoter — meaning it is only expressed in p16+ senescent cells; when the mice were fed AP20187 (a synthetic dimerizer drug that activates the caspase), only senescent (p16+) cells were selectively killed; no harm to non-senescent cells; the results: mice that received AP20187 from 3 months of age had significant delay in onset of sarcopenia, cataracts, and fat loss; mice that received AP20187 starting at 12 months (old, with established senescence burden) had REVERSAL of some senescent phenotypes; importantly: neither treated group had a significant increase in cancer — a key safety concern, since senescence is tumor-suppressive; Baker 2016 (Nature): the follow-up; genetically normal (non-progeroid) mice treated with AP20187 — the result: 17–27% extension of median lifespan AND healthspan; confirmed that senescence drives aging in physiologically normal mice, not just in artificially accelerated progeria models; these two papers together remain the strongest causal evidence that cellular senescence is not a passenger in aging but a driver

the inflammatory storm — the SASP (senescence-associated secretory phenotype) is the collection of bioactive molecules secreted by senescent cells; key SASP components: IL-6 (interleukin-6): major pro-inflammatory cytokine; associated with cardiovascular disease, sarcopenia, cognitive decline, and cancer progression; IL-8 (CXCL8): neutrophil and macrophage recruiter; amplifies inflammation; MMP-3, MMP-9, MMP-12 (matrix metalloproteinases): degrade extracellular matrix; disrupt tissue architecture; implicated in atherosclerosis plaque instability; PAI-1 (plasminogen activator inhibitor-1): promotes fibrosis; TGF-β: profibrotic; GROα, IP-10, RANTES: additional inflammatory chemokines; why SASP is context-dependent: SASP is not purely harmful — in acute settings (wound healing, embryogenesis, immune surveillance of tumors), SASP cytokines attract immune cells to clear the senescent cell; the problem is chronic SASP in aged tissue where immune clearance is impaired; the SASP regulatory pathways: NF-κB is the primary transcriptional driver of SASP; mTOR enhances SASP translation; GATA4 is a novel SASP regulator; p38 MAPK also activates SASP; these regulatory pathways are drug targets: rapamycin inhibits mTORC1 → reduces SASP; NF-κB inhibitors reduce SASP (but with systemic immunosuppression concerns); paracrine senescence: SASP factors can induce senescence in adjacent normal cells — the "zombie cells spread" phenomenon; this creates a senescence propagation cascade that accelerates tissue aging non-cell-autonomously

dasatinib + quercetin, first senolytic — the concept of senolytics (drugs that selectively kill senescent cells) emerged from a key observation: senescent cells upregulate anti-apoptotic pathways (BCL-2, BCL-XL, PI3K-AKT) to survive — "they don't want to die"; Zhu et al. 2015 (Aging Cell): systematic screen of senescent cell survival pathways; dasatinib (a BCL-2/BCL-XL inhibitor and tyrosine kinase inhibitor approved for leukemia) combined with quercetin (a flavonoid that inhibits PI3K and BCL-xL) synergistically killed senescent human preadipocytes and other senescent cell types while sparing non-senescent cells; the first human clinical trial: Hickson et al. 2019 (EBioMedicine): N=14 patients with idiopathic pulmonary fibrosis (IPF, a disease with high senescent cell burden); dasatinib 100mg + quercetin 1,000mg daily for 3 days; then 3 weeks washout; 3 cycles total (intermittent dosing — a key feature of senolytics, since they work by clearing existing senescent cells, not by preventing new formation); results: 6-minute walk distance improved; reduced senescent cell markers in adipose tissue biopsies (p16, p21 mRNA) and in plasma SASP markers; this was a small, uncontrolled study; the subsequent trials: DAMASCUS trial (ongoing): large RCT of D+Q in multiple age-related conditions; SToMP-AD trial: D+Q in Alzheimer's disease (senescent cells in brain are a proposed driver of neuroinflammation); the challenge: dasatinib is an FDA-approved cancer drug with significant side effects (pleural effusion, hepatotoxicity, cytopenias); quercetin is generally safe; the combination requires physician supervision; dosing interval: weekly or bi-weekly pulsed dosing appears better than chronic daily dosing

the supplement-accessible senolytic — fisetin (a flavonoid found in strawberries, apples, persimmons, and onions — concentrated in strawberries at ~160 μg/g) is one of the most studied naturally occurring senolytics; Yousefzadeh et al. 2018 (EBioMedicine): fisetin reduced senescent cell burden in multiple tissues of naturally aged mice; most potent senolytic flavonoid in a screen of 10 candidates; extended median lifespan by ~10% in old (17+ month) mice when started late in life; mechanism: fisetin inhibits PI3K-AKT and reduces BCL-2/BCL-XL expression → selectively removes cells dependent on these pathways for survival (senescent cells are disproportionately dependent); human pharmacokinetic data: fisetin has poor oral bioavailability (~10% absorbed); high inter-individual variation due to gut microbial metabolism; lipid-phase or nanoparticle formulations improve bioavailability; clinical trial: AFFIRM-LITE (Mayo Clinic): N=60, fisetin 20mg/kg for 2 consecutive days per month in older adults with adipose tissue senescence assessment; results pending; alternative senolytics under investigation: navitoclax (ABT-263): potent BCL-2/BCL-XL inhibitor; highly effective senolytic in mouse models; but causes thrombocytopenia (platelet destruction) limiting clinical use; piperlongumine: alkaloid; in preclinical studies only; HSP90 inhibitors: induce senescent cell death; the key message about supplement-accessible senolytics: the evidence in humans is still early; mouse-to-human translation in aging biology has historically been difficult; fisetin is being studied, not established; the established intervention remains D+Q under clinical protocols